Sanofi to acquire Origimm Biotechnology
Paris: Sanofi announced today it entered into an agreement to acquire Origimm Biotechnology GmbH, an Austrian privately owned biotechnology company specializing in the discovery of virulent skin microbiome components and antigens from bacteria causing skin disease, such as acne.
With this acquisition, Sanofi continues executing its global Play to Win strategy, pursuing growth opportunities and building an industry-leading vaccines pipeline.
The transaction will add ORI-001 to Sanofi's early-stage pipeline. ORI-001 is a therapeutic vaccine candidate for acne vulgaris based on recombinant proteins, which entered preliminary clinical studies in Q3 2021.
In parallel, Sanofi is working to develop additional antigen versions and expects to leverage its next-generation mRNA platform in a comprehensive Ph1/2 trial to start in 2023.
"We are looking forward to combining our expertise and strengths to continue developing innovative solutions for prevention and treatment of the skin microbiome-associated diseases, such as common acne" says Sanya Selak, PhD, Founder & CEO/CSO of Origimm. "Together with such a strong partner like Sanofi, we will strive to creating a paradigm shift in treatment of skin diseases and many other microbiome-associated disorders and infections, for which current medical solutions are inadequate."
The acquisition is expected to close early December 2021.
Read also: Sanofi, Chinese tech giant Baidu ink pact for mRNA algorithm
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.